Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth G Saag

Showing results (11-20 of 374) with videos related to

Pageof 38
Sort By:
Expert Opinion on Drug Safety|February 25, 2009
Glucocorticoids and the risk of osteoporosisLiron Caplan, Kenneth G Saag
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2025
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in OsteoporosisGiovanni Adami, Kenneth G Saag
The Journal of Rheumatology|January 1, 2003
Balancing bones and bucks among new glucocorticoid usersKenneth G Saag, Maria Pisu
Current Women'S Health Reports|September 10, 2003
Osteoporosis: evaluation and treatmentSonia Bajaj, Kenneth G Saag
Current Opinion in Rheumatology|May 3, 2019
Glucocorticoid-induced osteoporosis updateGiovanni Adami, Kenneth G Saag
Rheumatology (Oxford, England)|November 23, 2017
How to use bisphosphonates safely and optimallyAprajita Jagpal, Kenneth G Saag
Reviews in Endocrine & Metabolic Disorders|October 18, 2006
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?Sumapa Chaiamnuay, Kenneth G Saag
Current Rheumatology Reports|May 8, 2008
The use of zoledronic acid for osteoporosisAmy Warriner, Kenneth G Saag
Current Rheumatology Reports|May 8, 2008
Therapeutic advances in calcium and vitamin D for osteoporosisAmy Warriner, Kenneth G Saag
Current Rheumatology Reports|May 25, 2019
Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid ArthritisGiovanni Adami, Kenneth G Saag
Pageof 38

Showing results (11-20 of 374) with videos related to

Sort By:
Pageof 38
Expert Opinion on Drug Safety|February 25, 2009
Glucocorticoids and the risk of osteoporosisLiron Caplan, Kenneth G Saag
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2025
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in OsteoporosisGiovanni Adami, Kenneth G Saag
The Journal of Rheumatology|January 1, 2003
Balancing bones and bucks among new glucocorticoid usersKenneth G Saag, Maria Pisu
Current Women'S Health Reports|September 10, 2003
Osteoporosis: evaluation and treatmentSonia Bajaj, Kenneth G Saag
Current Opinion in Rheumatology|May 3, 2019
Glucocorticoid-induced osteoporosis updateGiovanni Adami, Kenneth G Saag
Rheumatology (Oxford, England)|November 23, 2017
How to use bisphosphonates safely and optimallyAprajita Jagpal, Kenneth G Saag
Reviews in Endocrine & Metabolic Disorders|October 18, 2006
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?Sumapa Chaiamnuay, Kenneth G Saag
Current Rheumatology Reports|May 8, 2008
The use of zoledronic acid for osteoporosisAmy Warriner, Kenneth G Saag
Current Rheumatology Reports|May 8, 2008
Therapeutic advances in calcium and vitamin D for osteoporosisAmy Warriner, Kenneth G Saag
Current Rheumatology Reports|May 25, 2019
Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid ArthritisGiovanni Adami, Kenneth G Saag
Pageof 38